Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 6/20 | 0.47 |
| ▸ | PPARA | Q07869 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.46 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13342845 | 0.83 | TSHR (0.55) | SMN1; SMN2HPGDNLRP1NCEH1ALOX15 | |
| SCHEMBL23706586 | 0.81 | PPARG (0.55) | SMN1; SMN2PPARGPPARACYP11B1CYP11B2 | |
| SCHEMBL1714978 | 0.80 | CYP4F2 (0.51) | SMN1; SMN2PPARGPPARAHPGDCYP11B1 | |
| SCHEMBL22372542 | 0.79 | PPARG (0.47) | SMN1; SMN2PPARGPPARACYP11B1CYP11B2 | |
| SCHEMBL13104134 | 0.77 | NCEH1 (0.43) | NCEH1 | |
| SCHEMBL9730220 | 0.77 | PPARG (0.57) | PPARGPPARACYP11B1CYP11B2USP30 | |
| SCHEMBL29517939 | 0.76 | LMNA (0.54) | SMN1; SMN2PPARGPPARANCEH1CYP11B1 | |
| SCHEMBL25762484 | 0.76 | TRPA1 (0.56) | SMN1; SMN2HPGDCYP11B2ALOX15ALDH1A1 | |
| SCHEMBL22372583 | 0.76 | LMNA (0.54) | SMN1; SMN2PPARGPPARANCEH1CYP11B1 | |
| SCHEMBL13091281 | 0.76 | FAAH (0.43) | NCEH1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47047-E1 | 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents | ASTRAZENECA AB (SE) | 2018-09-18 | — | — | US | disclosed |
| EP-2234979-B1 | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, process for their production and their use as anti-inflammatory agents | BAYER IP GMBH (DE) | 2016-05-25 | — | — | EP | disclosed |
| US-8680117-B2 | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AG (DE) | 2014-03-25 | — | — | US | disclosed |
| CN-103396300-A | Quinolinone compound, a process for producing same and use thereof as anti-inflammatory agent | BAYER SCHERING PHARMA AG | 2013-11-20 | — | — | CN | disclosed |
| CN-101868448-B | 5- [ (3,3, 3-trifluoro-2-hydroxy-1-arylpropyl) amino ] -1H-quinolin-2-ones, process for their preparation and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AG | 2013-06-12 | — | — | CN | disclosed |
| US-8394958-B2 | 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents | Bayer Pharma AG (DE) | 2013-03-12 | — | — | US | disclosed |
| US-20130005766-A1 | 5-[(3,3,3-TRIFLUORO-2-HYDROXY-1-ARYLPROPYL)AMINO]-1H-QUINOLIN-2-ONES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Bayer Pharma AG (DE) | 2013-01-03 | — | — | US | disclosed |
| EP-2234979-A1 | 5-Ý(3,3,3-TRIFLUORO-2-HYDROXY-1-ARYLPROPYL)AMINO¨-1H-QUINOLIN-2-ONES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009065503-A1 | 5-[(3,3,3-TRIFLUORO-2-HYDROXY-1-ARYLPROPYL)AMINO]-1H-QUINOLIN-2-ONES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-05-28 | — | — | WO | disclosed |
| US-20090137564-A1 | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, A Process for Their Production and Their Use as Anti-inflammatory Agents | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | disclosed |
| EP-2062880-A1 | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005766-A1 | 5-[(3,3,3-TRIFLUORO-2-HYDROXY-1-ARYLPROPYL)AMINO]-1H-QUINOLIN-2-ONES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | IL1B, PTGES2, PTGES | SMN1; SMN2 4730/4885PPARG 452/4885PPARA 546/4885 |
| US-20090137564-A1 | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, A Process for Their Production and Their Use as Anti-inflammatory Agents | IL1B, PTGES2, PTGES | SMN1; SMN2 4730/4885PPARG 452/4885PPARA 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.